Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 4/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29155775 | 0.93 | ELANE (0.34) | SPRELANEEGFRPLATALDH1A1 | |
| SCHEMBL1662681 | 0.86 | SPR (0.33) | SPRELANEPLATALDH1A1MAPT | |
| SCHEMBL1663399 | 0.81 | ELANE (0.40) | ELANEEGFRALDH1A1MAPTCYP2C9 | |
| SCHEMBL29277951 | 0.80 | KDM4E (0.39) | ELANEEGFRALDH1A1MAPTCYP2C9 | |
| SCHEMBL12795980 | 0.78 | HIF1A (0.31) | SPR | |
| SCHEMBL1663214 | 0.76 | TLR9 (0.36) | SPRELANEALDH1A1MAPTCYP2C9 | |
| SCHEMBL21355224 | 0.75 | PLAT (0.41) | SPRPLATALDH1A1MAPTCYP2C9 | |
| SCHEMBL1662835 | 0.73 | SMURF2 (0.37) | — | |
| SCHEMBL29277955 | 0.73 | ELANE (0.38) | ELANEEGFRALDH1A1MAPTCYP2C9 | |
| SCHEMBL23905478 | 0.71 | ELANE (0.38) | ELANEEGFRALDH1A1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-06-20 | — | — | US | disclosed |
| EP-4308229-A1 | INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| EP-4308564-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117355523-A | Polycyclic inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022197763-A1 | INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197789-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-3765459-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Shire Human Genetic Therapies, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019178129-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2011050284-A1 | PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050284-A1 | PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352356-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | SPR 98/4885ELANE 97/4885EGFR 3271/4885 |
| US-20240199613-A1 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | SPR 189/4885ELANE 81/4885EGFR 2728/4885 |
| US-20190284182-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | SPR 98/4885ELANE 97/4885EGFR 3271/4885 |
| US-10730874-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | SPR 98/4885ELANE 97/4885EGFR 3271/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | SPR 98/4885ELANE 97/4885EGFR 3271/4885 |
| US-20240226106-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | SPR 99/4885ELANE 73/4885EGFR 2848/4885 |
| US-20200317667-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | SPR 98/4885ELANE 97/4885EGFR 3271/4885 |
| US-20230078513-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | SPR 98/4885ELANE 97/4885EGFR 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.